FDA Brief

Warning letters Drugs

FDA warning letter to

Siddha Flower Essences, LLC., dba Siddha Remedies

High riskIssued Nov 4, 2025Posted Nov 18, 2025Center for Drug Evaluation and Research (CDER)

FDA cites Siddha Remedies, a maker of children's homeopathic drugs, for untested water and botanicals and microbial contamination.

What happened

FDA inspected the company's drug manufacturing facility in Oxnard, California, from April 22 to 29, 2025, and found the company had stopped testing its purchased purified water in 2022 while continuing to use it in pediatric drugs, and had not tested for Burkholderia cepacia complex, a bacterium linked to infections. Inspectors also found that a finished pediatric product, Temper Tamer lot S22-26424D, was released without testing for objectionable microorganisms, and that out-of-limit microbial results were not properly investigated. Separately, FDA reviewed the firm's drug listings in its electronic listing system and found the human over-the-counter homeopathic listings had not been updated or certified, and that animal drugs were made in a facility not registered as an animal drug manufacturer.

What FDA found

  1. The company did not test each lot of purchased purified water and botanical ingredients for identity, purity, strength and quality, and did not verify that suppliers' own test results were reliable.

    21 CFR 211.84(d)(1), (d)(2), (d)(6)
  2. The company stopped testing its purified water in 2022 but kept using it in children's drugs, and never tested it for Burkholderia cepacia complex, a contamination risk in water-based products.

    21 CFR 211.84(d)(1), (d)(2)
  3. Out-of-limit microbial results on finished product were not fully investigated, with no root cause or effective corrective action identified, and the company could not document that the contaminated batch was destroyed.

    21 CFR 211.192
  4. Temper Tamer lot S22-26424D was released without testing for total counts or absence of objectionable microorganisms.

    21 CFR 211.165(b)
  5. The quality control unit did not oversee manufacturing: procedures were not followed, batch records were not reviewed before release, contract testing labs were not qualified, preservative effectiveness was not tested, and production controls were not established.

    21 CFR 211.22, 211.22(a), 211.22(d), 211.160(b), 211.100(a)
  6. The company did not update or certify its human OTC homeopathic drug listings, and it made animal drugs in a facility not registered as an animal drug manufacturer, listing them under its human drug registration.

    Section 510(j) of the FD&C Act, 21 U.S.C. 360(j); 21 CFR Part 207

What FDA wants

FDA tells the company to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, including independent reviews of its material, investigation and quality systems, test results for components and retained batches, and a plan for notifying customers or recalling product if testing shows substandard quality. FDA also recommends engaging a qualified CGMP consultant to do a six-system audit before the firm seeks resolution of its compliance status.

Who should pay attention

  • brands that buy homeopathic or botanical finished products from this contract manufacturer
  • retailers and consumers of children's homeopathic remedies
  • manufacturers using purchased purified water or botanicals without incoming testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk